![](https://i.cbc.ca/ais/1.2840184,1717264016248/full/max/0/default.jpg?im=Crop%2Crect%3D%288%2C0%2C203%2C114%29%3BResize%3D%281180%29)
![](https://i.cbc.ca/ais/1.2840184,1717264016248/full/max/0/default.jpg?im=Crop%2Crect%3D%288%2C0%2C203%2C114%29%3BResize%3D%281180%29)
In 2010, the Canadian government licensed Iowa company NewLink Genetics to carry out clinical trials and be the sole producer of an ebola vaccine, VSV-EBOV. Now, four years on, critics say that process has been too slow and the delay is costing lives.